EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group

Giovanni Corso, Sherry Shen, Carmen Criscitiello, Rita Mukhtar, Lauren Gamble, Elena Guerini Rocco, Filippo Pesapane, Luca Nicosia, Komal Jhaveri, Beatrice Taurelli Salimbeni, Giulia Massari, Eleonora Meduri und 13 weitere

Cancer Treatment Reviews · 2025-11 · 140 · 103001

DOI: 10.1016/j.ctrv.2025.103001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-11. Verfasst von Giovanni Corso und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Mil…. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Lobular. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umberto Veronesi Foundation, Terri Brodeur Breast Cancer Foundation, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive lobular carcinoma (ILC) represents approximately 10-15% of all breast cancers and is defined by a unique discohesive morphology due to loss of E-cadherin. Despite its prevalence, ILC has been historically underrepresented in clinical and translational research, contributing to diagnostic, therapeutic, and prognostic uncertainties. This narrative review, conducted by the Invasive Lobular Carcinoma Research Group, synthesizes current evidence on ILC with expert perspectives to inform future research and clinical strategies. We highlight the distinct biology of ILC, including characteristic genomic alterations (e.g., CDH1, PIK3CA, ERBB2 mutations) and its relationship with endocrine sensitivity and limited immune infiltration. Diagnostic challenges are underscored by ILC's subtle imaging presentation and underestimation of tumor extent on mammography and ultrasound, with MRI and contrast-enhanced mammography offering improved accuracy. The review discusses evolving surgical approaches, axillary staging considerations, and radiotherapy strategies, with an emphasis on adapting techniques to ILC's infiltrative growth. Endocrine therapy remains central for hormone receptor-positive ILC, with emerging evidence supporting CDK4/6 inhibitors and extended endocrine therapy in high-risk cases. Investigational therapies targeting ILC-enriched mutations and synthetic lethality mechanisms (e.g., ROS1 inhibition in CDH1-deficient tumors) hold promise for personalized treatment. This comprehensive review identifies knowledge gaps and advocates for histology-specific clinical trials, biomarker-driven treatment strategies, and tailored imaging and surgical techniques to improve outcomes for patients with ILC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, LobularHumansFemale

Stichwörter der Autor:innen

E-cadherinEndocrine therapyInvasive lobular carcinoma (ILC)Neoadjuvant treatmentPrecision oncology

Autor:innen und Institutionen

  • Division of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giovanni.corso@ieo.it.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, the United States of America. Electronic address: ShenS1@mskcc.org.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy. Electronic ad…
  • Division of Surgical Oncology, University of California, San Francisco, San Francisco, the United States of America. Electronic address: Rita.Mukhtar@ucsf.edu.
  • Department of General Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, the United States of America. Electronic address: gamblel1@mskcc.org.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: Elena.GueriniRocco@ieo.it.

Förderung

  • Umberto Veronesi Foundation
  • Terri Brodeur Breast Cancer Foundation
  • Ministero della Salute

Zitieren

APA

Corso, G., Shen, S., Criscitiello, C., Mukhtar, R., Gamble, L., Rocco, E. G., Pesapane, F., Nicosia, L., Jhaveri, K., Salimbeni, B. T., Massari, G., Meduri, E., De Scalzi, A. M., Concardi, A., Magnoni, F., Mamtani, A., Pareja, F., Leonardi, M. C., Sacchini, V., …, & Robson, M. E. (2025). Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group. Cancer Treatment Reviews, 140, 103001. https://doi.org/10.1016/j.ctrv.2025.103001

Vancouver

Corso G, Shen S, Criscitiello C, Mukhtar R, Gamble L, Rocco EG, et al. Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group. Cancer Treatment Reviews. 2025;140:103001. doi:10.1016/j.ctrv.2025.103001

BibTeX
@article{Corso2025,
  author = {Corso, Giovanni and Shen, Sherry and Criscitiello, Carmen and Mukhtar, Rita and Gamble, Lauren and Rocco, Elena Guerini and Pesapane, Filippo and Nicosia, Luca and Jhaveri, Komal and Salimbeni, Beatrice Taurelli and Massari, Giulia and Meduri, Eleonora and De Scalzi, Alessandra Margherita and Concardi, Alberto and Magnoni, Francesca and Mamtani, Anita and Pareja, Fresia and Leonardi, Maria Cristina and Sacchini, Virgilio and Bogani, Giorgio and Vecchia, Carlo La and Presti, Daniele and Colleoni, Marco Angelo and Veronesi, Paolo and Robson, Mark E},
  title = {Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {140},
  pages = {103001},
  doi = {10.1016/j.ctrv.2025.103001}
}
Kostenlos starten →